COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become a global epidemic and poses a major threat to public health. In addition to COVID-19 manifesting as a respiratory disease, patients with severe disease also have complications in e...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-10-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S075333222200957X |
| _version_ | 1798003039500500992 |
|---|---|
| author | Penghui Li Ying Liu Ziqi Cheng Xiaorui Yu Yinxiong Li |
| author_facet | Penghui Li Ying Liu Ziqi Cheng Xiaorui Yu Yinxiong Li |
| author_sort | Penghui Li |
| collection | DOAJ |
| description | Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become a global epidemic and poses a major threat to public health. In addition to COVID-19 manifesting as a respiratory disease, patients with severe disease also have complications in extrapulmonary organs, including liver damage. Abnormal liver function is relatively common in COVID-19 patients; its clinical manifestations can range from an asymptomatic elevation of liver enzymes to decompensated hepatic function, and liver injury is more prevalent in severe and critical patients. Liver injury in COVID-19 patients is a comprehensive effect mediated by multiple factors, including liver damage directly caused by SARS-CoV-2, drug-induced liver damage, hypoxia reperfusion dysfunction, immune stress and inflammatory factor storms. Patients with chronic liver disease (especially alcohol-related liver disease, nonalcoholic fatty liver disease, cirrhosis and hepatocellular carcinoma) are at increased risk of severe disease and death after infection with SARS-CoV-2, and COVID-19 aggravates liver damage in patients with chronic liver disease. This article reviews the latest SARS-CoV-2 reports, focusing on the liver damage caused by COVID-19 and the underlying mechanism, and expounds on the risk, treatment and vaccine safety of SARS-CoV-2 in patients with chronic liver disease and liver transplantation. |
| first_indexed | 2024-04-11T12:01:41Z |
| format | Article |
| id | doaj.art-483232de94344d12a0219a19524a7b76 |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-04-11T12:01:41Z |
| publishDate | 2022-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-483232de94344d12a0219a19524a7b762022-12-22T04:24:49ZengElsevierBiomedicine & Pharmacotherapy0753-33222022-10-01154113568COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment managementPenghui Li0Ying Liu1Ziqi Cheng2Xiaorui Yu3Yinxiong Li4Center for Health Research, Guangdong Provincial Key Laboratory of Biocomputing, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China; University of Chinese Academy of Sciences, Beijing, China; Key Laboratory of Stem Cell and Regenerative Medicine, CAS Key Laboratory of Regenerative Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, ChinaCenter for Health Research, Guangdong Provincial Key Laboratory of Biocomputing, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China; University of Chinese Academy of Sciences, Beijing, China; Key Laboratory of Stem Cell and Regenerative Medicine, CAS Key Laboratory of Regenerative Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, ChinaCenter for Health Research, Guangdong Provincial Key Laboratory of Biocomputing, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China; University of Chinese Academy of Sciences, Beijing, China; Key Laboratory of Stem Cell and Regenerative Medicine, CAS Key Laboratory of Regenerative Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, ChinaCenter for Health Research, Guangdong Provincial Key Laboratory of Biocomputing, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China; University of Chinese Academy of Sciences, Beijing, China; Key Laboratory of Stem Cell and Regenerative Medicine, CAS Key Laboratory of Regenerative Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, ChinaCenter for Health Research, Guangdong Provincial Key Laboratory of Biocomputing, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China; University of Chinese Academy of Sciences, Beijing, China; Key Laboratory of Stem Cell and Regenerative Medicine, CAS Key Laboratory of Regenerative Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China; State Key Laboratory of Respiratory Disease, Guangzhou, China; China-New Zealand Joint Laboratory on Biomedicine and Health, Guangzhou, China; Corresponding author at: Center for Health Research, Guangdong Provincial Key Laboratory of Biocomputing, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become a global epidemic and poses a major threat to public health. In addition to COVID-19 manifesting as a respiratory disease, patients with severe disease also have complications in extrapulmonary organs, including liver damage. Abnormal liver function is relatively common in COVID-19 patients; its clinical manifestations can range from an asymptomatic elevation of liver enzymes to decompensated hepatic function, and liver injury is more prevalent in severe and critical patients. Liver injury in COVID-19 patients is a comprehensive effect mediated by multiple factors, including liver damage directly caused by SARS-CoV-2, drug-induced liver damage, hypoxia reperfusion dysfunction, immune stress and inflammatory factor storms. Patients with chronic liver disease (especially alcohol-related liver disease, nonalcoholic fatty liver disease, cirrhosis and hepatocellular carcinoma) are at increased risk of severe disease and death after infection with SARS-CoV-2, and COVID-19 aggravates liver damage in patients with chronic liver disease. This article reviews the latest SARS-CoV-2 reports, focusing on the liver damage caused by COVID-19 and the underlying mechanism, and expounds on the risk, treatment and vaccine safety of SARS-CoV-2 in patients with chronic liver disease and liver transplantation.http://www.sciencedirect.com/science/article/pii/S075333222200957XSARS-CoV-2COVID-19Liver injuryChronic liver diseaseLiver transplantVaccine |
| spellingShingle | Penghui Li Ying Liu Ziqi Cheng Xiaorui Yu Yinxiong Li COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management Biomedicine & Pharmacotherapy SARS-CoV-2 COVID-19 Liver injury Chronic liver disease Liver transplant Vaccine |
| title | COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management |
| title_full | COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management |
| title_fullStr | COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management |
| title_full_unstemmed | COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management |
| title_short | COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management |
| title_sort | covid 19 associated liver injury clinical characteristics pathophysiological mechanisms and treatment management |
| topic | SARS-CoV-2 COVID-19 Liver injury Chronic liver disease Liver transplant Vaccine |
| url | http://www.sciencedirect.com/science/article/pii/S075333222200957X |
| work_keys_str_mv | AT penghuili covid19associatedliverinjuryclinicalcharacteristicspathophysiologicalmechanismsandtreatmentmanagement AT yingliu covid19associatedliverinjuryclinicalcharacteristicspathophysiologicalmechanismsandtreatmentmanagement AT ziqicheng covid19associatedliverinjuryclinicalcharacteristicspathophysiologicalmechanismsandtreatmentmanagement AT xiaoruiyu covid19associatedliverinjuryclinicalcharacteristicspathophysiologicalmechanismsandtreatmentmanagement AT yinxiongli covid19associatedliverinjuryclinicalcharacteristicspathophysiologicalmechanismsandtreatmentmanagement |